Model-Based Meta-Analysis (MBMA) has emerged as a powerful tool for integrating data across clinical trials and generating insights that efficiently inform drug development and regulatory decision-making. This webinar will unpack two distinct MBMA methodologies: modeling absolute outcomes and relative treatment effects.
Using a mix of simulated and real-world case studies, this webinar will cover:
- Choosing the Right Modeling Approach
When to apply absolute outcome vs. relative effect models based on clinical and development objectives. - Maximizing Impact with Covariates
Differentiating between prognostic and predictive covariates and how they influence model applications, plus best practices for covariate exploration. - Informing Decisions with Simulations
How MBMA-based simulations can improve trial design, support treatment comparisons, and guide go/no-go decisions. - Ensuring Model Credibility
Techniques for evaluating model fit and credibility to ensure reliable, decision-ready results. - Applying MBMA in the Real World
Case studies showing how MBMA informs regulatory submissions, product strategy, and development planning.
お申込みはこちら
Matt Zierhut, PhD MBA
Vice President, MBMA Capability Lead, Certara Drug Development Solutions
マットは、公開された臨床結果データをMBMAを用いて開発、商業、規制戦略に統合しています。Mattは臨床開発チームと密接に連携し、最も重要な意思決定を行う際にMBMAが最適な効果を発揮するよう、活用しています。
お申込みはこちら
